Wockhardt financials

Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹929cr+25.9% on Q1 FY26
Net profit
₹107cr−₹108 cr in Q1 FY26
EBITDA margin
20.7%+10.9 pts on Q1 FY26
EPS
₹6.55−₹5.53 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue929738+25.9%
EBITDA19272.0+166.7%
EBITDA margin20.7%9.8%+10.9 pts
Profit before tax116−109—
Net profit107−108—
EPS₹6.55−₹5.53—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹929 crNet profit₹107 crNet margin11.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
30,997————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
62962953450590.0
341341304303308
2,1252,1251,8592,1121,887
32,834————
3,5643,3733,0122,7982,651
—+12.0%+7.6%+5.5%—
77265239339.0101
21.7%19.3%13.1%1.4%3.8%
546425176−184−150
414199−57.0−472−621
11.6%5.9%−1.9%−16.9%−23.4%
₹25.25₹13.15−₹2.90−₹28.58−₹34.51
—+553.2%+89.8%+17.2%—
—390−22.0219153
—−136−94.0−59.0−42.0
254254−116160111
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

WOCKPHARMA₹1,913.40

Wockhardt Ltd.

· Pharma & Health
₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹30,997 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————30,997.1
- Cash, Equiv & ST Investments90.0505.0534.0629.0629.0
+ Minority Interest308.0303.0304.0341.0341.0
+ Total Debt1,887.02,112.01,859.02,125.02,125.0
Enterprise Value————32,834.1
Revenue2,651.02,798.03,012.03,373.03,564.0
Growth %, YoY—+5.5+7.6+12.0—
EBITDA101.039.0393.0652.0772.0
Margin %3.811.3913.0519.3321.66
EBIT-150.0-184.0176.0425.0546.0
Net Income-621.0-472.0-57.0199.0414.0
Margin %-23.43-16.87-1.895.9011.62
EPS, Adj (current shares)-34.51-28.58-2.9013.1525.25
Growth %, YoY—+17.2+89.8+553.2—
Cash from Operations153.0219.0-22.0390.0—
Capital Expenditures-42.0-59.0-94.0-136.0—
Free Cash Flow111.0160.0-116.0254.0254.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Wockhardt financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Wockhardt (NSE: WOCKPHARMA) had a market capitalisation of ₹31,151 crore at the 29 October 2026 close (₹1,922.90 a share), a PE ratio of 76.2 on the last four quarters' profit and a price-to-book ratio of 6.31. In FY26 its consolidated net profit attributable to shareholders was ₹213 crore on revenue of ₹3,373 crore; in Q1 FY27 (April–June 2026) it was ₹106 crore. Its debt-to-equity ratio was 0.40 on 31 March 2026. Promoters held 49.32% of the shares on 30 September 2026.

Share price used
₹1,922.90 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Wockhardt at a glance · consolidated

Market cap
₹31,151 Crat ₹1,922.90 · 29 Oct close
PE ratio (last 4 quarters)
76.2146.2 on FY26 profit
Price to book (PB)
6.31book value ₹304.94 a share
ROE (FY26)
4.6%+5.8 pts vs FY25ROCE 6.5%
Debt to equity
0.40net debt ₹1,463 Cr
Promoter holding
49.32%+0.2 pts vs 30 Jun 202630 September 2026
Net worth
₹4,940 Cr+13.5% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹254 Cr
EPS (FY26)
₹13.12

Questions

What is the Wockhardt PE ratio today?

Wockhardt's PE ratio is 76.2 at the 29 October 2026 close (₹1,922.90 a share): a market capitalisation of ₹31,151 crore divided by consolidated net profit attributable to shareholders of ₹409 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹213 crore) it is 146.2.

What is the Wockhardt PB ratio (price to book value)?

Wockhardt's price-to-book (PB) ratio is 6.31 at the 29 October 2026 close: a market capitalisation of ₹31,151 crore divided by shareholders' equity (book value) of ₹4,940 crore on 31 March 2026. That is a book value of ₹304.94 per share against a share price of ₹1,922.90.

What is the Wockhardt net worth?

Wockhardt's net worth — shareholders' equity in its consolidated balance sheet — was ₹4,940 crore on 31 March 2026, up 13.5% from ₹4,353 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹31,151 crore at the 29 October 2026 close.

What is the Wockhardt market cap?

Wockhardt's market capitalisation was ₹31,151 crore at the 29 October 2026 close: 16.2 crore shares at ₹1,922.90 each.

Is Wockhardt debt free?

No. Wockhardt had borrowings of ₹2,125 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.40. Its cash and current investments were ₹662 crore, so its net debt was ₹1,463 crore.

What is the Wockhardt EPS?

Wockhardt's basic earnings per share (EPS) were ₹13.12 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹25.20.

What is the Wockhardt debt to equity ratio?

Wockhardt's debt-to-equity ratio was 0.40 on 31 March 2026: borrowings of ₹2,125 crore against total equity of ₹5,281 crore. A year earlier, on 31 March 2025, it was 0.40.

What is the Wockhardt book value per share?

Wockhardt's book value per share was ₹304.94 on 31 March 2026: shareholders' equity of ₹4,940 crore divided by the 16.2 crore shares in issue, up 13.5% from ₹268.70 a year earlier. The share price at the 29 October 2026 close was ₹1,922.90.

What is the Wockhardt free cash flow?

In FY26, Wockhardt generated ₹390 crore of cash from operations and spent ₹136 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹254 crore. In FY25 it was −₹116 crore.

What is the Wockhardt ROE and ROCE?

In FY26, Wockhardt's return on equity (ROE) was 4.6% and its return on capital employed (ROCE) was 6.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −1.2% and ROCE 3.2%.

What is the Wockhardt shareholding pattern?

On 30 September 2026, Wockhardt's shares were held by promoters 49.32%, foreign portfolio investors (FII/FPI) 7.02%, domestic institutions (DII) 9.00% (including mutual funds at 5.99%) and retail and other non-institutional investors 34.64%. Over the year, FII holding was down 0.08 percentage points from 7.10% and DII holding was down 2.01 percentage points from 11.01%.

What are the Wockhardt latest quarterly results?

Wockhardt's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit attributable to shareholders ₹106 crore, against a loss of ₹90 crore in Q1 FY26; revenue from operations ₹929 crore, up 25.9% year on year.

What is the Wockhardt promoter holding?

Promoters held 49.32% of Wockhardt on 30 September 2026, up 0.24 percentage points from 49.08% the previous quarter and up 0.24 percentage points from 49.08% a year earlier, according to the shareholding pattern filed with NSE.

What is the Wockhardt revenue and profit in FY26?

In FY26 (April 2025–March 2026), Wockhardt's consolidated net profit attributable to shareholders was ₹213 crore, against a loss of ₹47 crore in FY25, on revenue from operations of ₹3,373 crore (up 12.0%).

When are the Wockhardt next results?

Wockhardt will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.

How does Wockhardt compare with its peers?

On FY26 consolidated figures, against Biocon, Syngene International and Aster DM Healthcare: Wockhardt's operating margin of 12.6% is the second highest of the four (Biocon 8.9%, Syngene International 12.5%, Aster DM Healthcare 13.7%; peer average 11.7%); its return on equity of 4.6% is the third highest of the four (Biocon 1.4%, Syngene International 6.6%, Aster DM Healthcare 9.7%; peer average 5.9%); its revenue growth over three years of 8.4% a year is the second highest of the four (Biocon 14.9% a year, Syngene International 5.4% a year, Aster DM Healthcare −27.0% a year; peer average −2.2% a year).

How does the Wockhardt PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Wockhardt's PE ratio is 146.2, the second highest of the four: Biocon 148.7, Syngene International 50.8 and Aster DM Healthcare 90.7, a peer average of 96.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Wockhardt vs Biocon: how do they compare?

In FY26, Wockhardt earned net profit attributable to shareholders of ₹213 crore on revenue of ₹3,373 crore, against ₹386 crore on ₹16,927 crore for Biocon. Wockhardt's operating margin was 12.6% (Biocon 8.9%) and its return on equity 4.6% (Biocon 1.4%). At the 29 October 2026 close, Wockhardt's market capitalisation was ₹31,151 crore against ₹57,346 crore for Biocon, and its PE ratio on FY26 profit 146.2 against 148.7.

Where do these Wockhardt figures come from?

From Wockhardt's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.